Yahoo Web Search

Search results

1. • 

     FDA sets review date for Merck's KEYTRUDA in mesothelioma treatment By Investing.com

     Investing.com· 5 days ago

     Merck & Co., Inc., a global healthcare leader, has announced that the U.S. Food and Drug...

2. • Summit Therapeutics' stock surges as lung-cancer treatment vies with Merck's blockbuster

     Morningstar· 4 days ago

     Shares of Summit Therapeutics Inc. (SMMT) jumped more than 270% Thursday after the company said its experimental cancer drug outperformed Merck & Co. Inc ...

3. • 

     Summit Therapeutics sees stock soar 272% after lung cancer clinical trial - Silicon Valley Business...

     The Business Journals· 3 days ago

     Summit (Nasdaq: SMMT) — led by the team that scored success with blood cancer drug developer...

4. • 

     ASCO 2024: Rakuten’s photoimmunotherapy and Keytruda combo shows efficacy in HNSCC

     Clinical Trials Arena via Yahoo Finance· 6 days ago

     This potentially causes membrane damage in cancer cells, leading to selective necrosis of cancer...

5. • 

     ‘I can’t explain why’: Does this dog dewormer cure cancer? These Facebook groups say yes

     The Daily Dot· 4 days ago

     Three months later, the cancer had grown. From a cattle farm in Louisiana where she’s helping a...

6. • Tumors shrink for 62% of patients in Merck study

     Becker’s Hospital Review· 5 days ago

     In a phase 2/3 trial investigating the efficacy of Keytruda with two chemotherapies, tumors shrank among 3 in 5 patients with pleural mesothelioma, Merck said May 29. It often ...

7. • 

     Merck Reaches $1.3 Billion Deal for Eye-Drug Company EyeBio

     The Wall Street Journal· 5 days ago

     In recent years, Chief Executive Rob Davis has been doing deals to lessen Merck’s reliance on the...

8. • 

     Merck to buy eye-focused drug developer EyeBio for as much as $3 billion

     CNBC· 5 days ago

     Merck said in February it was in the market for deals of up to $15 billion, and has already struck...

9. • Experimental Therapy Shows Promise in Pancreatic C | Newswise

     Newswise· 4 days ago

     Immunotherapy drugs alone have not shown to be responsive to pancreatic cancer. The findings were presented at the American Society of Clinical Oncology 2024 annual meeting ...

10. • Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors...

      The Pilot News· 2 days ago

      Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein.